JP2011136988A5 - - Google Patents

Download PDF

Info

Publication number
JP2011136988A5
JP2011136988A5 JP2010269172A JP2010269172A JP2011136988A5 JP 2011136988 A5 JP2011136988 A5 JP 2011136988A5 JP 2010269172 A JP2010269172 A JP 2010269172A JP 2010269172 A JP2010269172 A JP 2010269172A JP 2011136988 A5 JP2011136988 A5 JP 2011136988A5
Authority
JP
Japan
Prior art keywords
group
ophthalmic composition
acid
silicone hydrogel
hydrogel contact
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010269172A
Other languages
Japanese (ja)
Other versions
JP2011136988A (en
JP5688954B2 (en
Filing date
Publication date
Application filed filed Critical
Priority to JP2010269172A priority Critical patent/JP5688954B2/en
Priority claimed from JP2010269172A external-priority patent/JP5688954B2/en
Publication of JP2011136988A publication Critical patent/JP2011136988A/en
Publication of JP2011136988A5 publication Critical patent/JP2011136988A5/ja
Application granted granted Critical
Publication of JP5688954B2 publication Critical patent/JP5688954B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (12)

（Ａ）ネオスチグミン及びその塩からなる群より選択される少なくとも１種と、（Ｂ）グリチルリチン酸、アミノエチルスルホン酸、アスパラギン酸、コンドロイチン硫酸、及びこれらの塩からなる群より選択される少なくとも１種とを含有する、シリコーンハイドロゲルコンタクトレンズ用眼科組成物。   (A) at least one selected from the group consisting of neostigmine and its salt; and (B) at least one selected from the group consisting of glycyrrhizic acid, aminoethylsulfonic acid, aspartic acid, chondroitin sulfate, and salts thereof. An ophthalmic composition for a silicone hydrogel contact lens. （Ａ）成分として、メチル硫酸ネオスチグミンを含む、請求項１に記載のシリコーンハイドロゲルコンタクトレンズ用眼科組成物。   The ophthalmic composition for a silicone hydrogel contact lens according to claim 1, comprising (A) component neostigmine methylsulfate. （Ｂ）成分として、グリチルリチン酸二カリウム、アミノエチルスルホン酸、アスパラギン酸カリウム、アスパラギン酸マグネシウム、アスパラギン酸マグネシウム・カリウム及びコンドロイチン硫酸ナトリウムからなる群より選択される少なくとも１種を含む、請求項１又は２に記載のシリコーンハイドロゲルコンタクトレンズ用眼科組成物。   The component (B) includes at least one selected from the group consisting of dipotassium glycyrrhizinate, aminoethylsulfonic acid, potassium aspartate, magnesium aspartate, magnesium potassium aspartate, and sodium chondroitin sulfate. The ophthalmic composition for silicone hydrogel contact lenses according to 2. （Ａ）成分の総量１００重量部当たり、（Ｂ）成分の総量が２０〜５０００００重量部である、請求項３に記載のシリコーンハイドロゲルコンタクトレンズ用眼科組成物。The ophthalmic composition for silicone hydrogel contact lenses according to claim 3, wherein the total amount of component (B) is 20 to 500,000 parts by weight per 100 parts by weight of component (A). 点眼剤である、請求項１〜４のいずれか一項に記載のシリコーンハイドロゲルコンタクトレンズ用眼科組成物。 The ophthalmic composition for a silicone hydrogel contact lens according to any one of claims 1 to 4 , which is an eye drop. 眼科組成物に（Ａ）ネオスチグミン及びその塩からなる群より選択される少なくとも１種と、（Ｂ）グリチルリチン酸、アミノエチルスルホン酸、アスパラギン酸、コンドロイチン硫酸、及びこれらの塩からなる群より選択される少なくとも１種とを配合することを含む、該眼科組成物に非イオン性シリコーンハイドロゲルコンタクトレンズに対する角膜上皮細胞の接着抑制作用を付与する方法。The ophthalmic composition is selected from the group consisting of (A) at least one selected from the group consisting of neostigmine and salts thereof, and (B) glycyrrhizic acid, aminoethylsulfonic acid, aspartic acid, chondroitin sulfate, and salts thereof. A method for imparting an action of inhibiting the adhesion of corneal epithelial cells to a nonionic silicone hydrogel contact lens to the ophthalmic composition, comprising blending at least one selected from the group consisting of: 眼科組成物に（Ａ）ネオスチグミン及びその塩からなる群より選択される少なくとも１種と、（Ｂ）グリチルリチン酸、アミノエチルスルホン酸、アスパラギン酸、コンドロイチン硫酸、及びこれらの塩からなる群より選択される少なくとも１種とを配合することを含む、該眼科組成物にイオン性シリコーンハイドロゲルコンタクトレンズへの花粉タンパク質の蓄積を抑制する作用を付与する方法。The ophthalmic composition is selected from the group consisting of (A) at least one selected from the group consisting of neostigmine and salts thereof, and (B) glycyrrhizic acid, aminoethylsulfonic acid, aspartic acid, chondroitin sulfate, and salts thereof. A method of imparting an action of suppressing the accumulation of pollen protein to an ionic silicone hydrogel contact lens to the ophthalmic composition, comprising blending at least one selected from the group consisting of: 眼科組成物に（Ａ）ネオスチグミン及びその塩からなる群より選択される少なくとも１種と、（Ｂ）グリチルリチン酸、アミノエチルスルホン酸、アスパラギン酸、コンドロイチン硫酸、及びこれらの塩からなる群より選択される少なくとも１種とを配合することを含む、該眼科組成物にシリコーンハイドロゲルコンタクトレンズへの細菌付着増大を抑制する作用を付与する方法。The ophthalmic composition is selected from the group consisting of (A) at least one selected from the group consisting of neostigmine and salts thereof, and (B) glycyrrhizic acid, aminoethylsulfonic acid, aspartic acid, chondroitin sulfate, and salts thereof. A method of imparting an action of suppressing an increase in bacterial adhesion to a silicone hydrogel contact lens to the ophthalmic composition, comprising blending at least one selected from the group consisting of: 眼科組成物に（Ａ）ネオスチグミン及びその塩からなる群より選択される少なくとも１種と、（Ｂ）アスパラギン酸及びこれらの塩からなる群より選択される少なくとも１種とを配合することを含む、該眼科組成物にシリコーンハイドロゲルコンタクトレンズの摩擦を低減する作用を付与する方法。Including (A) at least one selected from the group consisting of neostigmine and a salt thereof and (B) at least one selected from the group consisting of aspartic acid and a salt thereof in the ophthalmic composition, A method for imparting an action of reducing friction of a silicone hydrogel contact lens to the ophthalmic composition. （Ａ）ネオスチグミン及びその塩からなる群より選択される少なくとも１種と、（Ｂ）グリチルリチン酸、アミノエチルスルホン酸、アスパラギン酸、コンドロイチン硫酸、及びこれらの塩からなる群より選択される少なくとも１種とを含有する眼科組成物からなる、シリコーンハイドロゲルコンタクトレンズの摩擦の低減剤。(A) at least one selected from the group consisting of neostigmine and its salt; and (B) at least one selected from the group consisting of glycyrrhizic acid, aminoethylsulfonic acid, aspartic acid, chondroitin sulfate, and salts thereof. A friction reducing agent for silicone hydrogel contact lenses, comprising an ophthalmic composition comprising: シリコーンハイドロゲルコンタクトレンズに適用される眼科組成物からなる疲れ目改善剤であって、前記眼科組成物が、（Ａ）ネオスチグミン及びその塩からなる群より選択される少なくとも１種と、（Ｂ）グリチルリチン酸、アミノエチルスルホン酸、アスパラギン酸、コンドロイチン硫酸、及びこれらの塩からなる群より選択される少なくとも１種とを含有する、疲れ目改善剤。A fatigue eye improving agent comprising an ophthalmic composition applied to a silicone hydrogel contact lens, wherein the ophthalmic composition is (A) at least one selected from the group consisting of neostigmine and a salt thereof, and (B) An agent for improving fatigue eyes, comprising glycyrrhizic acid, aminoethylsulfonic acid, aspartic acid, chondroitin sulfate, and at least one selected from the group consisting of these salts. シリコーンハイドロゲルコンタクトレンズに適用される眼科組成物からなる目のピント調節機能改善剤であって、前記眼科組成物が、（Ａ）ネオスチグミン及びその塩からなる群より選択される少なくとも１種と、（Ｂ）グリチルリチン酸、アミノエチルスルホン酸、アスパラギン酸、コンドロイチン硫酸、及びこれらの塩からなる群より選択される少なくとも１種とを含有する、目のピント調節機能改善剤。An eye focus adjustment function improving agent comprising an ophthalmic composition applied to a silicone hydrogel contact lens, wherein the ophthalmic composition is (A) at least one selected from the group consisting of neostigmine and a salt thereof; (B) An eye focus control function improving agent containing glycyrrhizic acid, aminoethylsulfonic acid, aspartic acid, chondroitin sulfate, and at least one selected from the group consisting of these salts.
JP2010269172A 2009-12-02 2010-12-02 Ophthalmic composition for silicone hydrogel contact lens Active JP5688954B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2010269172A JP5688954B2 (en) 2009-12-02 2010-12-02 Ophthalmic composition for silicone hydrogel contact lens

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009274827 2009-12-02
JP2009274827 2009-12-02
JP2010269172A JP5688954B2 (en) 2009-12-02 2010-12-02 Ophthalmic composition for silicone hydrogel contact lens

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014254700A Division JP5941524B2 (en) 2009-12-02 2014-12-17 Ophthalmic composition for silicone hydrogel contact lens

Publications (3)

Publication Number Publication Date
JP2011136988A JP2011136988A (en) 2011-07-14
JP2011136988A5 true JP2011136988A5 (en) 2014-09-25
JP5688954B2 JP5688954B2 (en) 2015-03-25

Family

ID=44348778

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010269172A Active JP5688954B2 (en) 2009-12-02 2010-12-02 Ophthalmic composition for silicone hydrogel contact lens
JP2014254700A Active JP5941524B2 (en) 2009-12-02 2014-12-17 Ophthalmic composition for silicone hydrogel contact lens

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014254700A Active JP5941524B2 (en) 2009-12-02 2014-12-17 Ophthalmic composition for silicone hydrogel contact lens

Country Status (1)

Country Link
JP (2) JP5688954B2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6213715B2 (en) * 2013-06-27 2017-10-18 キョーリンリメディオ株式会社 Multi-component eye drops
JP6315755B2 (en) * 2013-10-02 2018-04-25 ロート製薬株式会社 Foreign eye feel relief eye drops
JP6471292B2 (en) * 2014-12-04 2019-02-20 株式会社メニコンネクト Ophthalmic solution
TWI651095B (en) * 2017-10-18 2019-02-21 晶碩光學股份有限公司 Antiallergic ophthalmic product
JP2020132536A (en) * 2019-02-14 2020-08-31 参天製薬株式会社 Aqueous pharmaceutical composition containing cromoglycate or salt thereof
JP2019218369A (en) * 2019-08-07 2019-12-26 ロート製薬株式会社 Eye drops for alleviating foreign body sensation
JP7178470B1 (en) 2021-05-17 2022-11-25 ロート製薬株式会社 ophthalmic composition

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006219476A (en) * 2004-12-28 2006-08-24 Rohto Pharmaceut Co Ltd Ocular locally applying preparation
JP4919666B2 (en) * 2005-01-26 2012-04-18 ロート製薬株式会社 Planoprofen-containing composition
JP2008024701A (en) * 2006-06-21 2008-02-07 Rohto Pharmaceut Co Ltd Composition for soft contact lens comprising alginic acid or salt thereof

Similar Documents

Publication Publication Date Title
JP2011136988A5 (en)
JP2013006877A5 (en)
JP2014139241A5 (en)
WO2012118686A3 (en) Silicone hydrogel contact lenses
JP2016510727A5 (en)
BRPI0715431B8 (en) low-tack otolaryngological and ophthalmic device materials
JP2020070301A5 (en)
JP2011136986A5 (en)
JP2011132227A5 (en)
WO2013037479A8 (en) Ophthalmic compositions comprising prostaglandin f2 alpha derivatives and hyaluronic acid
JP2011136980A5 (en)
WO2012063237A3 (en) Buffered ophthalmic compositions and methods of use thereof
JP2014211652A5 (en)
BRPI0920951A2 (en) intraocular lens, method for correcting vision, method for making an ophthalmic lens
WO2007103349A3 (en) Devices, methods and compositions for presbyopia correction using ultrashort pulse lasers
NZ608202A (en) Agent for treatment of dry eye characterized by combining p2y2 receptor agonist and hyaluronic acid or salt thereof, method for treating dry eye, and use of the p2y2 receptor agonist and hyaluronic acid or salt thereof
JP2013523273A5 (en)
BR112013023830A2 (en) lens with multiconcave meniscus wall
EP2778749A3 (en) Presbyopia lens with pupil size correction based on level of refractive error
WO2010085267A3 (en) Low-tack ophthalmic and otorhinolaryngological device materials
WO2012118682A3 (en) Silicone hydrogel contact lenses with high freezable water content
JP2011098961A5 (en)
Weeks et al. Physical entrapment of hyaluronic acid during synthesis results in extended release from model hydrogel and silicone hydrogel contact lens materials
JP2014210807A5 (en)
EA201201239A1 (en) A composition comprising as active ingredients L-CARNITINE IN COMBINATION WITH hydroxykynurenine-O-BETA-DL-glucoside FOR PREVENTING AND / OR TREATING PATHOLOGIES eyes caused by ultraviolet radiation